Is MannKind Corp. overvalued or undervalued?

As of 9 November 2016, the valuation grade for MannKind Corp. has moved from does not qualify to risky. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 26, an EV to EBITDA of 13.61, and a PEG ratio of 0.06, which suggests a significant disparity in valuation compared to its peers.
In comparison, Catalyst Pharmaceuticals, Inc. has a more attractive P/E ratio of 14.87 and an EV to EBITDA of 8.36, indicating that MannKind Corp. is trading at a premium relative to this peer. Additionally, Mirum Pharmaceuticals, Inc., despite being classified as risky, shows a P/E ratio of -32.47, further highlighting the challenges faced by MannKind. The company's recent stock performance has lagged behind the S&P 500, with a year-to-date return of -40.98% compared to the index's 2.44%, reinforcing the notion that MannKind Corp. is currently overvalued.